<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03087773</url>
  </required_header>
  <id_info>
    <org_study_id>HS-2017-01</org_study_id>
    <nct_id>NCT03087773</nct_id>
  </id_info>
  <brief_title>Impact of EMpagliflozin on Cardiac Function and Biomarkers of Heart Failure in Patients With Acute MYocardial Infarction</brief_title>
  <acronym>EMMY</acronym>
  <official_title>Impact of EMpagliflozin on Cardiac Function and Biomarkers of Heart Failure in Patients With Acute MYocardial Infarction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Graz</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>United Arab Emirates University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Medical University of Vienna</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Landeskrankenhaus Feldkirch</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Paracelsus Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital Rudolfstiftung</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Klinikum Klagenfurt am Wörthersee</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Barmherzige Brüder Eisenstadt</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Kardinal Schwarzenberg Klinikum Schwarzach St. Veit</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Johannes Kepler University of Linz</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Landesklinikum Sankt Polten</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Landeskrankenhaus II Graz West</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Medical University of Graz</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is planned to investigate the impact of Empagliflozin on biomarkers of heart&#xD;
      failure in patients with myocardial infarction with and without type 2 diabetes mellitus&#xD;
      within 6 months after the event.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Type 2 diabetes mellitus (T2DM) is associated with an about two to three-fold increased risk&#xD;
      for cardiovascular events as compared to subjects without diabetes.&#xD;
&#xD;
      Sodium-dependent glucose cotransporter 2 (SGLT-2) is mainly expressed in human kidneys and&#xD;
      small intestinal cells. In the proximal tubule of the nephron SGLT-2 is responsible for the&#xD;
      reabsorption of approximately 90% of the filtrated glucose. Inhibition of SGLT-2 was shown to&#xD;
      increase renal glucose excretion and to lower glucose. Subsequently, a number of SGLT-2&#xD;
      inhibitors were developed and are currently approved for the treatment of type 2 diabetes.&#xD;
&#xD;
      Recently, Zinman et al published the results of the EMPA-REG-OUTCOME (Cardiovascular Outcome&#xD;
      Event Trial in Type 2 Diabetes Mellitus Patient) trial where the cardiovascular impact of a&#xD;
      glucose lowering regimen including Empagliflozin as compared to usual glucose control without&#xD;
      an SGLT-2 inhibitor was investigated. The trial demonstrated an unexpected reduction in the&#xD;
      primary composite endpoint, comprising cardiovascular death, non-fatal myocardial infarction&#xD;
      and non-fatal stroke. The reduction was mainly driven by a 38% relative risk reduction in&#xD;
      cardiovascular deaths; moreover they demonstrated an impressive 35% relative risk reduction&#xD;
      in the secondary endpoint hospitalization for heart failure. Of note, the beneficial effects&#xD;
      observed in the Empagliflozin group seem to occur very rapidly after commencing the&#xD;
      treatment, as suggested by the early separation of the Kaplan-Meier curves. However, the&#xD;
      mechanisms responsible for this finding remain unclear. Diuretic effects with subsequent&#xD;
      impact on hemodynamics or potential cardioprotective effects of glucagon, which levels rise&#xD;
      under the treatment with SGLT-2 inhibitors and the resulting rise in ketone bodies or a small&#xD;
      increase in hematocrit have been suggested.&#xD;
&#xD;
      The aim of our trial is to investigate whether Empagliflozin treatment commenced within 72-h&#xD;
      after acute myocardial infarction has an impact on heart failure in subjects with and without&#xD;
      diabetes mellitus type 2.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">May 11, 2017</start_date>
  <completion_date type="Anticipated">April 2, 2022</completion_date>
  <primary_completion_date type="Anticipated">March 2, 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>change of nt-proBNP levels</measure>
    <time_frame>26 weeks</time_frame>
    <description>Difference in the change of nt-proBNP levels between treatment groups from randomization to week 26</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>changes of ejection fraction</measure>
    <time_frame>26 weeks</time_frame>
    <description>Difference in the change of ejection fraction between treatment groups from randomization to week 26</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>changes of ejection fraction</measure>
    <time_frame>6 weeks</time_frame>
    <description>Difference in the change of ejection fraction between treatment groups from randomization to week 6</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>changes of left ventricular diastolic function</measure>
    <time_frame>26 weeks</time_frame>
    <description>Difference in the change of left ventricular diastolic function from randomization to week 26</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>changes of left ventricular diastolic function</measure>
    <time_frame>6 weeks</time_frame>
    <description>Difference in the change of left ventricular diastolic function from randomization to week 6</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>changes of nt-proBNP levels</measure>
    <time_frame>6 weeks</time_frame>
    <description>Difference in the change of nt-proBNP levels between treatment groups from randomization to week 6</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>changes of HbA1c</measure>
    <time_frame>26 weeks</time_frame>
    <description>Difference in the change of HbA1c between treatment groups from randomization to week 26 (in subjects with known diabetes mellitus Type 2)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>changes of body weight</measure>
    <time_frame>6 weeks</time_frame>
    <description>Difference in the change of body weight between treatment groups from randomization to week 6</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>changes of body weight</measure>
    <time_frame>26 weeks</time_frame>
    <description>Difference in the change of body weight between treatment groups from randomization to week 26</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>changes of blood beta-hydroxybutyrate levels</measure>
    <time_frame>6 weeks</time_frame>
    <description>Difference in the change of blood beta-hydroxybutyrate levels between the treatment groups from randomization to week 6</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>changes of blood beta-hydroxybutyrate levels</measure>
    <time_frame>26 weeks</time_frame>
    <description>Difference in the change of blood beta-hydroxybutyrate levels between the treatment groups from randomization to week 26</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of hospital re-admissions due to heart failure</measure>
    <time_frame>30 weeks</time_frame>
    <description>Difference in the number of hospital re-admissions due to heart failure between the treatment groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of hospital re-admissions for any cause</measure>
    <time_frame>30 weeks</time_frame>
    <description>Difference in the number of hospital re-admissions for any cause between the treatment groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>duration of hospital stay</measure>
    <time_frame>30 weeks</time_frame>
    <description>Difference in the duration of hospital stay between the treatment groups after initiation of the study treatment</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">476</enrollment>
  <condition>Acute Myocardial Infarction</condition>
  <arm_group>
    <arm_group_label>Empagliflozin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The subjects will receive Empagliflozin 10mg.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Oral Tablet</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The subjects will receive placebo.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Empagliflozin 10 mg</intervention_name>
    <description>The subject will receive Empagliflozin 10 mg orally once daily for 26 weeks.</description>
    <arm_group_label>Empagliflozin</arm_group_label>
    <other_name>Jardiance</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Oral Tablet</intervention_name>
    <description>The subject will receive Placebo orally once daily for 26 weeks.</description>
    <arm_group_label>Placebo Oral Tablet</arm_group_label>
    <other_name>Sugar pill</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Myocardial infarction with evidence of significant myocardial necrosis defined as a&#xD;
             rise in creatinine kinase &gt;800 U/l and a troponin T-level (or troponin I-level) &gt;10x&#xD;
             ULN (upper limit of normal). In addition at least 1 of the following criteria must be&#xD;
             the met:&#xD;
&#xD;
               -  Symptoms of ischemia&#xD;
&#xD;
               -  ECG (electrocardiogram) changes indicative of new ischemia (new ST-T changes or&#xD;
                  new LBBB)&#xD;
&#xD;
               -  Imaging evidence of new regional wall motion abnormality&#xD;
&#xD;
          2. 18 - 80 years of age&#xD;
&#xD;
          3. Informed consent has to be given in written form&#xD;
&#xD;
          4. eGFR (glomerular filtration rate) &gt; 45 ml/min/1.73m2&#xD;
&#xD;
          5. Blood pressure before first drug dosing: RR systolic &gt;110 mmHg&#xD;
&#xD;
          6. Blood pressure before first drug dosing: RR diastolic &gt;70 mmHg&#xD;
&#xD;
          7. ≤72h after myocardial infarction (after the performance of a coronary angiography)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Any other form of diabetes mellitus than type 2 diabetes mellitus, history of diabetic&#xD;
             ketoacidosis&#xD;
&#xD;
          2. Blood pH (potential hydrogen) &lt; 7,32&#xD;
&#xD;
          3. Known allergy to SGLT-2 inhibitors&#xD;
&#xD;
          4. Hemodynamic instability as defined by intravenous administration of catecholamine,&#xD;
             calcium sensitizers or phosphodiesterase inhibitors&#xD;
&#xD;
          5. &gt;1 episode of severe hypoglycemia within the last 6 months and treatment with insulin&#xD;
             or sulfonylurea&#xD;
&#xD;
          6. Females of childbearing potential without adequate contraceptive methods (i.e.&#xD;
             sterilization, intrauterine device, vasectomized partner; or medical history of&#xD;
             hysterectomy)&#xD;
&#xD;
          7. Acute symptomatic urinary tract infection (UTI) or genital infection&#xD;
&#xD;
          8. Patients currently being treated with any SGLT-2 inhibitor or having received&#xD;
             treatment with any SGLT-2 inhibitor within the 4 weeks prior to the screening visit&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Harald Sourij, Assoc.-Prof.</last_name>
    <role>Study Director</role>
    <affiliation>Medical University of Graz</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dirk von Lewinski, Assoc.-Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University of Graz</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Barmherzige Brüder Eisenstadt</name>
      <address>
        <city>Eisenstadt</city>
        <state>Burgenland</state>
        <zip>7000</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Klagenfurt am Wörthersee</name>
      <address>
        <city>Klagenfurt</city>
        <state>Kärnten</state>
        <zip>9020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum St. Pölten</name>
      <address>
        <city>St.Pölten</city>
        <state>Niederösterreich</state>
        <zip>3100</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kepler Universitätsklinikum Linz</name>
      <address>
        <city>Linz</city>
        <state>Oberösterreich</state>
        <zip>4021</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kardinal schwarzenberg Klinikum Schwarzach</name>
      <address>
        <city>Schwarzach Im Pongau</city>
        <state>Salzburg</state>
        <zip>5620</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VIVIT Institut am akademischen Lehrkrankenhaus Feldkirch</name>
      <address>
        <city>Feldkirch</city>
        <state>Vorarlberg</state>
        <zip>6800</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Landeskrankenhaus Graz II Standort West</name>
      <address>
        <city>Graz</city>
        <zip>8020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University of Graz</name>
      <address>
        <city>Graz</city>
        <zip>8036</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Uniklinikum Salzburg</name>
      <address>
        <city>Salzburg</city>
        <zip>5020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Krankenanstalt Rudolfstiftung</name>
      <address>
        <city>Vienna</city>
        <zip>1030</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AKH Vienna</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>March 17, 2017</study_first_submitted>
  <study_first_submitted_qc>March 22, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 23, 2017</study_first_posted>
  <last_update_submitted>November 4, 2021</last_update_submitted>
  <last_update_submitted_qc>November 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Biomarker</keyword>
  <keyword>Heart failure</keyword>
  <keyword>SGLT-2 inhibitor</keyword>
  <keyword>Empagliflozin</keyword>
  <keyword>Randomized controlled trial</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Infarction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Empagliflozin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

